Ultragenyx insider plans sale of 4,696 shares

Ultragenyx Pharmaceutical Inc. (RARE) has a planned sale of restricted securities reported by Howard Horn under a notice of proposed sale of securities.

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. (RARE) has a planned sale of restricted securities reported by Howard Horn under a notice of proposed sale of securities. The filing lists up to 4,696 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $117,024.32 and CUSIP 98489224, on the NASDAQ market. These shares were acquired as Restricted Stock and Performance Shares dated March 1, 2025.

The filing also lists securities sold during the past three months by Howard Horn: 4,698 common shares sold on July 1, 2026 for $155,644.74, and 4,653 common shares sold on June 1, 2026 for $110,601.81.

Key Figures

Planned shares to be sold: 4,696 shares Planned sale value: $117,024.32 Shares sold July 1, 2026: 4,698 shares +5 more

8 metrics

Planned shares to be sold 4,696 shares Common stock proposed for sale under the notice

Planned sale value $117,024.32 Aggregate market value of 4,696 common shares

Shares sold July 1, 2026 4,698 shares Common stock sold on 07/01/2026 by Howard Horn

Proceeds July 1, 2026 sale $155,644.74 Value of common shares sold on 07/01/2026

Shares sold June 1, 2026 4,653 shares Common stock sold on 06/01/2026 by Howard Horn

Proceeds June 1, 2026 sale $110,601.81 Value of common shares sold on 06/01/2026

CUSIP 98489224 Identifier for the common stock listed in the notice

Acquisition date of securities 03/01/2025 Date of Restricted Stock and Performance Shares acquisition

Key Terms

Restricted Stock, Performance Shares, Securities To Be Sold, Securities Sold During The Past 3 Months

4 terms

Restricted Stock financial

"Restricted Stock and Performance Shares"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Performance Shares financial

"Restricted Stock and Performance Shares"

Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.

Securities To Be Sold regulatory

"144: Securities To Be Sold"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing by RARE’s Howard Horn disclose?

The filing discloses a proposed sale of 4,696 common shares of Ultragenyx Pharmaceutical Inc. (RARE) with an aggregate value of $117,024.32, along with details of prior share sales during the last three months.

How many RARE shares does Howard Horn plan to sell under this Form 144?

Howard Horn plans to sell up to 4,696 common shares of Ultragenyx Pharmaceutical Inc. (RARE). These shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ market.

What is the value of the RARE shares covered by the proposed sale?

The proposed sale covers common shares with an aggregate market value of $117,024.32. This value is associated with 4,696 Ultragenyx Pharmaceutical Inc. (RARE) shares listed in the Form 144 notice.

What type of RARE securities is Howard Horn selling under Form 144?

The securities are common stock acquired as Restricted Stock and Performance Shares dated March 1, 2025. These instruments represent equity compensation in Ultragenyx Pharmaceutical Inc. (RARE).

What RARE share sales has Howard Horn made in the past three months?

Howard Horn sold 4,698 common shares on July 1, 2026 for $155,644.74 and 4,653 common shares on June 1, 2026 for $110,601.81, as reported in the Form 144 history section.

Which broker is handling Howard Horn’s proposed RARE stock sale?

The proposed sale of 4,696 Ultragenyx Pharmaceutical Inc. (RARE) common shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:19 PM Accepted by SEC EDGAR 08/03/2026 - 04:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001786335
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ULTRAGENYX PHARMACEUTICAL INC.
SEC File Number	001-36276
Address of Issuer	60 Leveroni Court Novato CALIFORNIA 94949
Phone	(415) 483-8800
Name of Person for Whose Account the Securities are To Be Sold	HOWARD HORN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4696	117024.32	98489224	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2025	Restricted Stock and Performance Shares	Issuer			4696	03/01/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
HOWARD HORN 60 Leveroni Court Novato CA 94949	Common	07/01/2026	4698	155644.74
HOWARD HORN 60 Leveroni Court Novato CA 94949	Common	06/01/2026	4653	110601.81

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock and performance shares during the period of 3/1/2025 through 3/1/2026.
Date of Notice	08/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/02/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Howard Horn
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)